| Title |
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2020
|
| DOI | 10.2147/dddt.s243787 |
| Pubmed ID | |
| Authors |
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, Michelle Harrison, Jianjun Zou, Lianshan Zhang, Stacey Luo, Michael Lahn, Howard Kallender, Andrea Mannucci, Catello Somma, Katherine Woods, Andreas Behren, Pablo Fernandez-Penas, Michael Millward, Tarek Meniawy |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Pakistan | 1 | 33% |
| Australia | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 18% |
| Student > Master | 2 | 6% |
| Researcher | 2 | 6% |
| Lecturer | 1 | 3% |
| Student > Ph. D. Student | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 18 | 55% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Nursing and Health Professions | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Neuroscience | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 19 | 58% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2020.
All research outputs
#15,065,223
of 25,806,763 outputs
Outputs from Drug Design, Development and Therapy
#807
of 2,283 outputs
Outputs of similar age
#191,818
of 385,152 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 39 outputs
Altmetric has tracked 25,806,763 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 385,152 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.